Survival curves for patients treated with PPV with or without combination chemotherapies. a-f) There was no significant survival advantage of combined chemotherapies (CC) in each intrinsic subtype, compared with the treatment by PPV alone. a) b) mrTNBC: PFS and OS, P = 0.467 and P = 0.347, respectively. c,d) luminal/HER2-negative type: PFS and OS, P = 0.220 and P = 0.850, respectively. e,f) HER2-positive type: PFS and OS, P = 0.296 and P = 0.957, respectively. HER2, human epidermal growth factor receptor 2; mrTNBC, metastatic recurrent triple negative breast cancer; OS, overall survival; PFS, progression-free survival; PPV, personalized peptide vaccination.